What are the guidelines for using bile acid sequestrants in pregnancy?

Bile Acid Sequestrants in Pregnancy

Bile acid sequestrants (cholestyramine 4-8 g/day or colestipol 5-10 g/day) are considered safe for use during pregnancy and are recommended as second-line agents for cholestasis-associated pruritus, though they must be given at least 4 hours apart from ursodeoxycholic acid (UDCA) to avoid interference with absorption. 1

Primary Indication and Clinical Context

Bile acid sequestrants (also called anion exchange resins) are used in pregnancy primarily for:

• Cholestasis-associated pruritus in conditions like primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and intrahepatic cholestasis of pregnancy (ICP)
• They serve as adjunctive therapy when UDCA alone provides insufficient symptom relief 1

Specific Dosing and Administration

The 2023 EASL guidelines provide clear dosing parameters:

• Cholestyramine: 4-8 g/day
• Colestipol: 5-10 g/day
• Critical timing requirement: Must be administered at least 4 hours after UDCA to prevent binding and reduced absorption of UDCA 1

Safety Profile

Bile acid sequestrants are among the only lipid-lowering agents officially approved for pregnancy, as they are not systemically absorbed and work locally in the gastrointestinal tract 2, 3. However, the evidence supporting their efficacy is notably limited—the guidelines acknowledge that evidence for cholestyramine and colestipol is "poor" while evidence for colesevelam is "non-existent" 1.

Critical Monitoring Requirements

Vitamin K Deficiency

Vitamin K deficiency must be actively monitored and corrected, as bile acid sequestrants can exacerbate this deficiency, particularly in women with:

• Pre-existing cholestasis
• Steatorrhea
• Concurrent rifampicin use 1

Practical monitoring approach:

• Check INR regularly in women on bile acid sequestrants
• Provide vitamin K supplementation when deficiency is documented or suspected
• Ensure neonates receive vitamin K at birth if mother was treated with sequestrants or rifampicin 1

Treatment Algorithm for Cholestasis-Associated Pruritus in Pregnancy

1. First-line: UDCA 10-20 mg/kg/day (start low at 10 mg/kg and titrate up) 1

2. If pruritus persists despite UDCA:

   • Add cholestyramine (4-8 g/day) or colestipol (5-10 g/day)
   • OR rifampicin (300-600 mg daily) 1
   • Administer sequestrants at least 4 hours after UDCA

3. Supportive measures (concurrent with pharmacotherapy):

   • Emollients to prevent skin dryness
   • Avoid hot baths/showers
   • Cooling gels (menthol-based) for affected areas
   • Keep nails shortened 1

Important Caveats

• Limited efficacy data: The weak recommendation (LoE 4) reflects that evidence for bile acid sequestrants in pregnancy-related cholestasis is limited, though they are considered safe 1
• Drug interactions: Beyond UDCA, sequestrants can bind other medications—consider timing of all oral medications
• Colesevelam lacks data: While cholestyramine and colestipol have some pregnancy experience, colesevelam has no evidence base in pregnancy 1
• Not for dyslipidemia in pregnancy: While sequestrants are the only approved lipid-lowering agents in pregnancy 2, 3, the primary obstetric indication is pruritus management, not lipid control

Comparison with Alternative Agents

When bile acid sequestrants fail to control symptoms:

• Rifampicin is an alternative with similar safety considerations (monitor for hepatotoxicity in 5% of cases; ensure neonatal vitamin K) 1
• Plasmapheresis or drainage may provide transient relief in severe, refractory cases 1